Kuala Lumpur News

listen to dailystraits.com - something different! podcast on goodpods

Kuala Lumpur, July 11: Samaiden Group Berhad (Samaiden), a leading renewable energy (RE) specialist, and Malaysian Genomics Resource Centre Berhad (Malaysian Genomics), a prominent genomics and biopharmaceutical specialist, have announced significant developments in their respective fields.
Samaiden’s subsidiary, Samaiden Sdn Bhd (SSB), has been awarded a contract worth RM181.34 million by Suria Infiniti Sdn. Bhd. to develop a 50MWac large-scale solar photovoltaic (PV) power plant in Mukim Sungai Petani, Kuala Muda, Kedah. The project, approved by the Energy Commission under the LSS4 program, is expected to contribute positively to Samaiden’s future earnings.

Chow Pui Hee
Chow Pui Hee.

Ir. Chow Pui Hee, Group Managing Director of Samaiden, expressed enthusiasm about the contract, emphasizing the company’s strategy of geographical diversification and its commitment to meeting the growing demand for RE solutions while supporting sustainability commitments.
Meanwhile, Malaysian Genomics’ subsidiary, MGRC Healthcare Sdn Bhd (MGRC-H), has entered into a supply agreement with DLF Engineering Pte Ltd (DLF) for the distribution of genetic screening tests and cell laboratory production services in Singapore.
DLF is a renowned engineering service and trade distribution company with a well-established network in the healthcare sector. This collaboration aligns with Malaysian Genomics’ strategy of expanding geographically and diversifying its customer base.

Azri Azerai
Azri Azerai.

Azri Azerai, Executive Chairman of Malaysian Genomics, expressed satisfaction with the partnership and highlighted the group’s plans to introduce and register additional products in Singapore, aiming to strengthen its presence in Southeast Asia.
Both Samaiden and Malaysian Genomics have been actively pursuing growth opportunities and exploring collaborations to expand their operations and reach.
Earlier this year, Malaysian Genomics entered into a strategic cooperation agreement with Toticell Limited, a regenerative healthcare specialist based in Dhaka, Bangladesh, focusing on musculoskeletal treatments.
These recent developments demonstrate the companies’ commitment to their respective industries and their efforts to deliver innovative solutions and services. The contracts and partnerships not only contribute to the growth and financial performance of Samaiden and Malaysian Genomics but also reflect their dedication to sustainability, renewable energy, and advancements in genomics and healthcare.

Leave a Reply